Form 4: Viracta Therapeutics Director Exercises Stock Options, Reports Ownership Change
SEC Form 4 Filing
Director Roger Pomerantz reports changes in beneficial ownership of Viracta Therapeutics stock following the exercise of restricted stock units.
Summary
- On August 25, 2024, Roger Pomerantz, a director of Viracta Therapeutics, Inc., executed transactions involving restricted stock units.
- Pomerantz acquired 9,034 shares of common stock through the exercise of restricted stock units at a price of $0.
- Following the transaction, Pomerantz directly owns 117,444 shares of Viracta Therapeutics common stock.
- Pomerantz also directly owns 27,103 restricted stock units.
Sentiment
Score: 5
Explanation: This is a neutral reporting of a standard transaction. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
This filing is a routine disclosure related to insider transactions and is a standard practice for publicly traded companies. It provides transparency to investors regarding the ownership changes of company insiders.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding insider activity.
- The exercise of options could slightly dilute existing shareholders' equity.
Key Dates
| Date | Description |
|---|---|
| November 25, 2021 | First Vesting Date for restricted stock units, where one-eighth (1/8th) of the RSU Award vested. |
| February 25, May 25, August 25, November 25 | Quarterly Vesting Dates for restricted stock units, where one-sixteenth (1/16th) of the RSU Award vests each quarter. |
| 08/25/2024 | Date of transaction where restricted stock units were exercised. |
| 09/12/2024 | Date of signature on the Form 4 filing. |
Keywords
Viracta Therapeutics, VIRX, Form 4, Beneficial Ownership, Roger Pomerantz, Director, Restricted Stock Units, Stock Options, Securities Exchange Act
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.